ResMed (RMD) Scheduled to Post Earnings on Thursday

ResMed (NYSE:RMD) will release its earnings data after the market closes on Thursday, April 25th. Analysts expect ResMed to post earnings of $1.93 per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

ResMed (NYSE:RMD) last posted its earnings results on Wednesday, January 24th. The medical equipment provider reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.81 by $0.07. ResMed had a net margin of 19.77% and a return on equity of 23.86%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.15 billion. During the same period last year, the firm posted $1.66 EPS. The firm’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, analysts expect ResMed to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

ResMed Stock Performance

NYSE:RMD opened at $180.35 on Tuesday. The company has a current ratio of 3.11, a quick ratio of 1.89 and a debt-to-equity ratio of 0.27. The firm has a 50-day moving average price of $186.14 and a two-hundred day moving average price of $171.04. ResMed has a twelve month low of $132.24 and a twelve month high of $243.52. The company has a market capitalization of $26.53 billion, a P/E ratio of 29.81, a price-to-earnings-growth ratio of 2.19 and a beta of 0.67.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 14th. Shareholders of record on Thursday, February 8th were paid a dividend of $0.48 per share. The ex-dividend date was Wednesday, February 7th. This represents a $1.92 annualized dividend and a dividend yield of 1.06%. ResMed’s dividend payout ratio is currently 31.74%.

Analyst Upgrades and Downgrades

RMD has been the topic of several analyst reports. JPMorgan Chase & Co. raised their price target on shares of ResMed from $160.00 to $195.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 9th. Needham & Company LLC raised their price target on shares of ResMed from $215.00 to $224.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Royal Bank of Canada raised their price target on shares of ResMed from $181.00 to $182.00 and gave the stock a “sector perform” rating in a research note on Thursday, January 25th. Mizuho reaffirmed a “buy” rating and set a $215.00 price target on shares of ResMed in a research note on Wednesday, March 27th. Finally, UBS Group raised their price target on shares of ResMed from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Thursday, January 25th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, ResMed currently has an average rating of “Moderate Buy” and an average target price of $199.20.

Insider Buying and Selling

In related news, General Counsel Michael J. Rider sold 200 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $173.25, for a total value of $34,650.00. Following the sale, the general counsel now directly owns 6,688 shares of the company’s stock, valued at $1,158,696. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other ResMed news, Director Peter C. Farrell sold 10,935 shares of ResMed stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $182.66, for a total transaction of $1,997,387.10. Following the transaction, the director now directly owns 157,404 shares of the company’s stock, valued at $28,751,414.64. The sale was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel Michael J. Rider sold 200 shares of ResMed stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $173.25, for a total transaction of $34,650.00. Following the transaction, the general counsel now directly owns 6,688 shares in the company, valued at $1,158,696. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,216 shares of company stock valued at $2,046,617. Insiders own 1.21% of the company’s stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.